Philippe Menu Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Monday, July 13th. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00. Following the completion of the transaction, the insider owned 228,387 shares in the company, valued at approximately $1,301,805.90. This trade represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total value of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total value of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.82, for a total value of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.

SOPHiA GENETICS Trading Up 1.6%

NASDAQ SOPH opened at $5.77 on Thursday. The company’s fifty day simple moving average is $5.21 and its 200-day simple moving average is $5.01. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.30. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The stock has a market cap of $484.05 million, a P/E ratio of -11.10 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Analyst Ratings Changes

Several research firms recently issued reports on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.50.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Perkins Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth $49,000. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS during the 1st quarter worth $50,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the fourth quarter worth $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at approximately $55,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.